Parkinson's disease (PD) is the second most common neurodegenerative disorder behind Alzheimer's disease. There are currently no therapies proven to halt or slow the progressive neuronal cell loss in PD. A better understanding of the molecular and cellular causes of PD is needed to develop disease-modifying therapies. PD is an age-dependent disease that causes the progressive death of dopamine-producing neurons in the brain. Loss of substantia nigra dopaminergic neurons results in locomotor symptoms such as slowness of movement, tremor, rigidity and postural instability. Abnormalities in other neurotransmitters, such as serotonin, may also be involved in both the motor and non-motor symptoms of PD. Most cases of PD are sporadic but many families show a Mendelian pattern of inherited Parkinsonism and causative mutations have been identified in genes such as Parkin, DJ-1, PINK1, alpha-synuclein and leucine rich repeat kinase 2 (LRRK2). Although the definitive causes of idiopathic PD remain uncertain, the activity of the antioxidant enzyme glutathione peroxidase 1 (Gpx1) is reduced in PD brains and has been shown to be a key determinant of vulnerability to dopaminergic neuron loss in PD animal models. Furthermore, Gpx1 activity decreases with age in human substantia nigra but not rodent substantia nigra. Therefore, we crossed mice deficient for both Parkin and DJ-1 with mice deficient for Gpx1 to test the hypothesis that loss-of-function mutations in Parkin and DJ-1 cause PD by increasing vulnerability to Gpx1 deficiency. Surprisingly, mice lacking Parkin, DJ-1 and Gpx1 have increased striatal dopamine levels in the absence of nigral cell loss compared to wild type, Gpx1 hippocampus. Stereological analysis indicated that the increased serotonin levels were not due to increased serotonergic projections. The results of our behavioral, neurochemical and immunohistochemical analyses reveal that PD-linked mutations in Parkin and DJ-1 cause dysregulation of neurotransmitter systems beyond the nigrostriatal dopaminergic circuit and that loss-of-function mutations in Parkin and DJ-1 lead to adaptive changes in dopamine and serotonin especially in the context of Gpx1 deficiency.
Introduction
Parkinson's disease (PD) is the most common neurodegenerative movement disorder and afflicts millions of people worldwide. The severity of the primary clinical symptoms, which include bradykinesia, resting tremor, rigidity, and postural instability, increases over the course of many years. Postmortem examinations reveal a profound and selective loss of dopaminergic neurons in the substantia nigra that project to the caudate and putamen of the dorsal striatum. The loss of dopaminergic innervation of the striatum underlies the primary clinical symptoms, which can be ameliorated with dopaminergic medications. Although the definitive cause of nigral dopamine neuron loss remains unknown, aging is the greatest risk factor for PD, consistent with the increased prevalence of PD in elderly populations. The capacity of cells to clear reactive oxygen species and repair oxidative damage to proteins, lipids and nucleic acids diminishes with age (Liddell et al., 2010), suggesting a potential role for cumulative oxidative stress in PD pathogenesis.
The majority of PD cases are idiopathic with no clear family history of Parkinsonian symptoms. However, genetic linkage studies of families with Mendelian patterns of inherited Parkinsonism have identified causal mutations in several genes (Corti et al., 2011; Dawson et al., 2010; Hattori, 2012; Horowitz and Greenamyre, 2010; Lopez and Sidransky, 2010; Varcin et al., 2012) . Among these are the loss-offunction mutations in the Parkin and DJ-1 genes that were the first to be causally linked to recessive Parkinsonism (Bonifati et al., 2003; Kitada et al., 1998) . Both Parkin and DJ-1 are widely expressed throughout the brain and other tissues (Kuhn et al., 2004; Shang et al., 2004; Shimura et al., 1999; Stichel et al., 2000; Xie et al., 2009 ) but it is not obvious why the loss of Parkin or DJ-1 function causes selective Neurobiology of Disease 62 (2014) 113-123 
